Cutler Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Cutler Group’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-200	Closed	-$1K	–	4734
2018 Q3	$1K	Buy	+200	New	+$15.2K	﹤0.01%	3920
2017 Q4	–	Sell	-5,200	Closed	-$43K	–	6148
2017 Q3	$43K	Sell	5,200 -1,000	-16%	-$60.5K	﹤0.01%	2382
2017 Q2	$21K	Sell	6,200 -200	-3%	-$16.4K	﹤0.01%	3384
2017 Q1	$7K	Sell	6,400 -11,200	-64%	-$833K	﹤0.01%	4447
2016 Q4	$20K	Buy	17,600 +8,800	+100%	+$639K	﹤0.01%	3483
2016 Q3	$3K	Sell	8,800 -16,400	-65%	-$909K	﹤0.01%	5496
2016 Q2	$227K	Buy	25,200 +10,300	+69%	+$429K	0.01%	1027
2016 Q1	$344K	Buy	14,900 +5,600	+60%	+$355K	0.02%	700
2015 Q4	$36K	Buy	+9,300	New	+$734K	﹤0.01%	2817

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Cutler Group's EGRX Position: Q1 2022 in Review

Cutler Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 803 shares — an estimated $40K sold.

Cutler Group first reported a position in EGRX in Q4 2015 and held it in 14 quarters. The position peaked at $236K in Q4 2015. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

Cutler Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Cutler Group sold 803 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $40K.
Cutler Group first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 14 quarters.
Cutler Group's Eagle Pharmaceuticals, Inc. position peaked at $236K in Q4 2015.
160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.